Lotfi R.,Kalmarzi R. N.,Roghani S. A. .2021 .A review on the immune responses against novel emerging coronavirus (SARS-CoV-2. Immunologic Research, 69(3) : 213-224.
Romano M.,Ruggiero A.,Squeglia F.,Maga G.,Berisio R. .2020 .A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells, 9(5) : 1267.
Albasry Z.,Al-Taie A. .2023 .Assessment of acceptance, concerns and side effects towards COVID-19 vaccination among the community: A cross-sectional study from Baghdad, Iraq. Clinical Epidemiology and Global Health, 20 : 101217.
Abdulla Z. A.,Al-Bashir S. M.,Al-Salih N. S.,Aldamen A. A.,Abdulazeez M. Z. .2021 .A summary of the SARS-CoV-2 vaccines and technologies available or under development. Pathogens, 10(7) : 788.
Fraussen J. .2022 .IgM responses following SARS-CoV-2 vaccination: insights into protective and pre-existing immunity. E Bio Medicine, 77 : 103922.
Harrington W. E.,Trakhimets O.,Andrade D. V.,Dambrauskas N.,Raappana A.,Jiang Y.,Sather D. N.,Reports Cell .2021 .Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. , 2(4) : 100253.
Khoury D. S.,Cromer D.,Reynaldi A.,Schlub T. E.,Wheatley A. K.,Juno J. A.,Davenport M. P. .2021 .Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 27(7) : 1205-1211.
Yaugel-Novoa M.,Bourlet T.,Paul S. .2022 .Role of the humoral immune response during COVID-19: guilty or not guilty?. Mucosal Immunology, 15(6) : 1170-1180.
Mcgonagle D. .2020 .Since January 2020 Elsevier has created a COVID19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. , : .
Ruggiero A.,Piubelli C.,Calciano L.,Accordini S.,Valenti M. T.,Dalle Carbonare,Zipeto L.,D. L. .2022 .SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID19-infected individuals. EBioMedicine, 77 : 103888.
Röltgen K.,Boyd S. D. .2021 .Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host & Microbe, 29(7) : 1063-1075.
Hickey T. E.,Kemp T. J.,Bullock J.,Bouk A.,Metz J.,Neish A.,Pinto L. A. .2023 .SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines. Human Vaccines & Immunotherapeutics, 19:2, : 2215677.
Chen X.,Hong J.,Deng L.,Weng H.,Huang T.,Wang L.,Yang J. .2023 .Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China. , 10 : 1240340.
Huang A. T.,Garcia-Carreras B.,Hitchings M. D.,Yang B.,Katzelnick L. C.,Rattigan S. M.,Cummings D. A. .2020 .A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nature communications, 11(1) : 4704.
Chan R. W. Y.,Liu S.,Cheung J. Y.,Tsun J. G. S.,Chan K. C.,Chan K. Y. Y.,Lam H. S. .2021 .The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines. , 12 : 744887-744887.
Selma-Royo M.,Bäuerl C.,Mena-Tudela D.,Aguilar-Camprubí L.,Pérez-Cano F. J.,Parra-Llorca A.,Collado M. C. .2022 .AntiSARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: A longitudinal study. Genome Medicine, 14(1) : 1-11.
Bahl K.,Senn J. J.,Yuzhakov O.,Bulychev A.,Brito L. A.,Hassett K. J.,Ciaramella G. .2017 .Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Molecular Therapy, 25(6) : 1316-1327.
Zheng B.,Peng W.,Guo M.,Huang M.,Gu Y.,Wang T.,Ming D. .1996 .Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID19. Chemical Engineering Journal (Lausanne, 418 : 129392-129392.
Bates T. A.,McBride S. K.,Leier H. C.,Guzman G.,Lyski Z. L.,Schoen D.,Tafesse F. G. .2022 .Vaccination before or after SARSCoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol, : eabn8014-eabn8014.